Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
← catalyst calendarNCT06380751 · readout in 1,217 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
788estimated
Sites
302
Countries
Argentina, Australia, Austria +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-01 | actual | When the study began enrolling |
| Primary completion | 2029-12-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Breast Cancer
Interventions
- Drug: Saruparib (AZD5305)
- Drug: Camizestrant
- Drug: Abemaciclib
- Drug: Ribociclib
- Drug: Palbociclib
- Drug: Fulvestrant
- Drug: Letrozole
- Drug: Anastrozole
- Drug: Exemestane
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (Arm 1 vs arm 2)
measured Up to approximately 64 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed